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ABSTRACT 
Microfocal CT was used to image the pulmonary arterial (PA) tree in rodent models of pulmonalY hypertension (PH). 
CT images were used to measure the aJierial tree diameter along the main a1terial trunk at several hydrostatic 
intravascular pressures and cnlculate distensibility. High~resolutioll planar allgiographic iluaging was also used to 
examine distal PA microstructure. Data on pulmonary artery trce morphology improves our understanding of vascular 
remodeling and response to treatments. Angiotensin n (ATn) has been identified as a mediator of vasoconstriction and 
proliferative mitotic function. ATII has been shown to promote vascular smooth muscle cell hypertrophy and 
hyperplasia as well as stimulate synthesis of extracellular matri..-x proteins. Available ATII is targeted through angiotensin 
converting enzyme inhibitors (ACE-Is). a method that has been used in animal modcls of PH to attenuate vascular 
remodeling and decrease pulmonary vascular resistance. In this study, we used rat models of chronic hypoxia to induce 
PH combined with partial left pulmonary artelY occlusion (arterial banding, PLPAO) to evaluate effects of tile ACE!, 
captopril, on pulmonary vascular hemodynamic and morphology, Male Sprague Dawley rats were placed in hypoxia 
(Fi02 0.1), "vith one group having underwent PLPAO threc days prior to the chronic hypoxia. After the twenty-first day 
of hypoxia exposure. treatment \vas started with captopril (20 mg/kg/day) for an additional twenty-one days. At the 
endpoint, lungs were excised and isolated to examine: pulmonlli), vascular resistance, ACE activity) pulmonary vessel 
morphology and biomechanics. Hematocrit and RVJLV+septwll ratio was also measured. CT planar images showed less 
vessel dropout· in rats treated with caplopril versus the non-treatment lungs. Distensibility data shows no change in rats 
treated with captopril in both chronic hypoxia (CH) and CH \vith PLPAO (CH+PLPAO) models. Hemodynatn.ic 
measurCl1lcnLs also show no change in the pulmonary vascular resistance with captopril treatrncnt in both CH and 
CH+PLPAO, 
Keywords: angiotensin, ACEI, microfocal CT, pulmonary hypertension, distensibility, planar angiogram) rat model 
1, INTRODUCTION 
Pediatric patients with congenital heart disease, specifically \vith left to right shunts, are known to develop pulmonary 
hypertcnsion (PH). Repair of the shunt at a young age decreases the risk of developing pulmonary hypertension but there 
are some patients that continue to develop elevated pulmonary vascular re:5istance.31. Some of these children have other 
co-morbidities that predispose them to PH, such as prematurity or chronic lung disease, The pathologic changes that 
occur in PH secondary to congenital heart disease are similar to changes that occur in idiopathic PH. Pathologically, 
there is hypertrophy and h:yperplasia of the media and, in some cases, development of plexiform icsions23•33 . In rat 
models of PH with prolonged vasoconstriction caused by chronic hypoxic exposure there is stimulation of vascular 
remodeling and extension of vascular smooth muscle cells in to more distal previously non-muscular arteries2,6,25,33. 
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Though the causes of PH are not fully known, hypoxia, inflammation, and endothelial injury are all known stimuli for 
the vasoconstriction and vascular remodeling that occurs in PH. Vasocons.lriction occurs due to 3n imbalance' between 
vasoconstrictor and vasodilator mediators in the pulmonary vascular bed lO. There is a decrease in vasodilators, nitric 
oxide and prostocyclin, and an inc.rease in vasoconstrictors, endothelin- l, and thromboxane AI. Prolonged 
vasoconstriction leads to vascular remodeling, w hich is most ly irreversible, as we know it. Current therapies often aim to 
change the balance between vasoactive mediators such as endothel in- l antagonists, prostocycli~ and nitric oxide. 
Although these therapies s low the progression of the disease, they do not reverse it. Some studies have looked at the 
mediators involved in vascular remo<ielillg ll,It>.21.J4 and -the. effects of modulating mediators to attenuate vascular 
remodeling. One such mediator is angiotensiu II. 
Angiotensin II (ATIl) has many effects on the vasculature. The two main A TIl mechanisms involve vasoconstrictive and 
mitogenic activity. /\. TIT is cr~ated by an enzymatic conversion of angiotensin I by angiotensin converting enzyme 
(ACE), which is primarily fOllnd in the lung. ACE has bee,ll shown to reduce vasodilatation by inactivation of 
bradykinin ". ATII promotes smooth muscle cell hypertrophy, hyperplasia and migration to the non-muscular pulmonary 
vasculaturc4,1 t. Expression of ACE has been shown to increm;c after exposure to C1-eo. Angiotensin converting enzyme 
inhibitor.; (A<:'Els) decrease available ATII . Studies have been done to examine lhe e llect of ACEI, on the development 
of increased pulmonary vascular resistance. ACEls modulate vascular remodeling and decreases pulmonary vascular 
resistance that occurs in chronic hypoxia~·I:!:.22,26 . Ho\-vever, previous studies have started ACEl treatment prior 10 or at 
the same time the stimuiuscausing PH and vascular remodeling (i.e. hypoxia or mOllocrotaline) was applied. This is a 
preventative model of PH and cannot be u5cd to infer treatment benetits in patients with established pulmonary 
hypert~nsion. Studies that have started therapy with an ACEl after establishment of pulmonary hypertension have mixed 
results: with some showing a beneficial decrease in pulmonary vascular resistance and others ~hO\ving no benefie· 15.~:!. 
Along with the d istal extension of smooth muscle celLo; irito non-muscular arteries and hyperplasia of the arterial media 
layer, studies have shown evidence of raTefactions and loss of a.rterioles6.'8,24~ which is thought to be an important 
component of PH. Other evidence of angiogenesis in thesystemjc vasculature in rats exposed to CH8,Q,JI may not be 
reflective of what is OCCUlTing in the puhnonruy vascular bed, although recent study by Howell et a1. shO\ved that rat 
exposed to CH have· increased blood vessel vo lume and length as well as increase capillary surface area9• Results from 
imaging experiments in this study provide further evidence of vessel rarefaction with chronic hypoxia induted PH. 
2. STUDY DESIGN 
This study was desif,'llcd to examine the effect of an orally ingested angiotensin converting enzyme inhibitor (captopril) 
on the pulmonary vasculature in rats with established pulmonary hypc-rtension. Toward this goal \\'e utilized male 
sprague dawley rats weighing 250-300gm ill two models of PH, one of chronic hypoxic (CH) exposure and a second of 
CH exposure after partial left. pulmonary artery banding. The Institutional Animal Care and Use Committee of the 
Zablocki V A Medical Center approved all protocols and procedures. In both the CH group (N ~ 8) and the CH + 
banding group (N = 8), half of the rats received treatment w ith captopril alter the first 2 I -days of exposure. A control 
group had partial left pulmonary artery banding, was ke.pt in normoxia, and did not receive captopri l (N = 4). 
2.1 Hypoxia 
Hypoxia chambers had a FiO, of 0.1 , which was achieved by blending room air with N,. The FiO, was monitored and 
maintainc-d for constant Fi02 at least twice daily. The rats were kept in the chamber except for food, water, weighing, 
and bedding and cage changes twice \vcckly. These maintenance routines took under 30 minutes to complete and all rats, 
except for the nonnoxics, were kept in CH for a total of 42-days. 
2.2 Partial LeIt Pulmonary Artery Occlusion 
Some rats underwent surgical partial Icft pulmonary artery occlusion (PLPAO) 3 days prior to placement in hypoxia 
chambers (N ,_. S). The rats Were anesthetizcd with a ,"bcutaneous injection of ketamine (75mglkg) and dormitor 
(O.5mg/kg). They were weighed and, once a sufficient plane of anesthesia was obtained, intubated with a 14 gnuge 
angine.th. placed on a ventilator (Harvard Apparatus model [nspira asv model# 55-7059) and ventilated with a peak 
pressure of 32 cmH,O, peep of 7 cmH,O, and an initial rate of 72 breaths/minute. The chest was opened at the fourth 
intercostal space and the left lung dellated. ntC left p ulmonary artery was identified and dissected away from the airway 
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and partially occluded using a loop of nylon suture around the artery. The lung was re-inflated by using s igh breaths of 
40 cmHzO peak pressure. _When the lung was fu lly fe-inflated the chest was closed in two layers using nylon sutllre. 
During skin closure each rat 'was given lOmg/kg of BaytrH subcutanoously and Antiscdan (l mg/kg) by intraperitoneal 
injection, When the rat began to spontaneously breath at a regular rate, the endotracheal tube was removed, They were 
placed on a heating pad, given 2ml of normal saline subculaneously and O,l-O'smg of Buprenex subcutaneously and 
were allowed to recover. 
2,J Cllptopri! 
The rats that received treatment with an ACEI were provided eaptopril (20mg/kg/day) in their drinking water, starting 
the 22nd day of eH exposure, 
2.4 Endpoint Studies 
Endpoint sUidies (day 42) included measurements ufhematocrit, body weight, RV/LV+scpturn ratio, FAPGG, dry lung 
weight . hemodynamics) and micro-CT imaging 10 measure distensibility. diameter, and the length of the main pulmonary 
tnmk, 
Each rat was anesthetized wilh sodium pentobarbital (40 mg/kg ip) and a midline sternolomy was performed, The cal 
was heparini<ed (200 lUlkg) by right ventricular injection, and a blood sample was removed for hematocrit 
determination. The trachea and pulmonary artery were cannulated, and the heart was cAc-ised for right ventricular free 
wall and lefl ventricle plus septwn weight dClcnninatlon. The lung was ventilated with a 15% 02~ 6 % CO2 in N2 gas 
mixture,3 mmHg end expiratoty prc-ssure and 8 mmHg end inspiratory pressure, The. lung was subjected to 2 or 3 brief 
peak inspiratory episodes of 12- 15 mmHg to eliminate any atelectasis that might have occurred during the cx<:ision. 
The lung was rinsed free of blood and perfused with a 37t:'c physiological salt solution containing 5% bovine senlDl 
alburnin. 
2,4,1 Hcmatoclit, RV ILV + septum Rotio, and HelDodynamics 
Blood drawn H:om the heart was centrifuged at 30,000 rpm for alleasl 2 minutes and the ratio of packed cells to plasma 
was Lt~cd to detemline hematocrit. Two samples were prepared from each rat and the average value reported, The heart 
was excised and the right ventricle was dissected ii'om the left ventricle and ventricular septum. Each was weigbed and 
tllC ratio was used to indicate rigbt ventricl~ar hypertrophy (RVH), A recirculation circuit was created with the excised 
lung with the physiologic saline solution with 5% bovine serum albumin. Hemodynamic studies were performed by 
measuring the puhnonary artery pressure at several flow rates from 0 to 40mllmin while maintaining a constant airway 
pressure of 6 mmHg. The flow was normalized to rat body weight for graphical analysis , 
2,4,2FAPGG 
N-[3-(2-furyl)-acryloIJ-L-phenyl-alanyglyclglycine (FAPGCi) is an ACE subs Irate u,ed to determine the activity of 
ACE, FAPGG is hydrolyzed to PAP and there is a resultant decrease in absorbance. at 340nmlli. FArGG is perfused 
through the IWlg for 50 sec then samples of the effluent arc obtained at 55 and 60 sec for the full lung, The effluent 
samples. were placed in a spectrometer and the absorbance measured and used <!s and indicator of the binding activity of 
ACE. ACE activity is presented as means surface area product (MSAP), 
2.4,3 Mlcrol'oca[ Angiography and CT Imaging sud Analysis 
The lung was immediately placed in the imaging chamber and ventilated v.ith the gas mixture listed above, An 
atmosphcriL-: n.~servoir of pcrt1uorooctyl bromide lPFOB), an X-ray contrast agent, was connected to the pulmonary 
artery cannuL1 via clamped 118 inch ID Tygon ulbing. The tubing was undamped and the physiologic saline solution in 
the lung was then replaced by PF03, Because, PFOB does not pass tbrollgh the capillary bed, it only fills the 
pulmonary arterial tree and intravascular pressures can be maintained hydrostatically. Accounting for the density of the 
PFOB, intravascular pressure was determined by measuring Ihe d ifference between the height of the surface of PFOB in 
the reservoir and the center of the lung. The arteries were conditioned by cycling the intravascular pressure from 0 to 30 
mmHg several times. Ventilation was halted during imaging, airway pressure was again maintained constant at 6 mmHg. 
The arterial pressure was sct to 30 mmHg, and the lungs were rotated in the x-ray beam of a custom built microfocal 
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imaging systeml4.l 8 at 1 (' increments to obtain 360 planar images. The pressure was lowered successively to 21, 12, and 6 
mmHg, \vith complete CT scans obtained at each presslrre {see Figure 4). Each scan took approximately 3 minutes. The 
lungs we·re then translated tmvard the· X-ray source and high-magnification planar images of each lung lobe were 
obtained at each intravascular pressure. 
Arterial distensibili ty was measured using previously published methods30. Drietly~ isotropic CT volumes of the isolated 
lungs wert:: obtained at each. of the four intravascular pressures. A Visualizatioll JVorksho{J (A VW ~ Analyze® Biomedical 
Imaging Resource (BIR) {It the Aiu}'o Cliflic17,?~,29 was used ·to segment and map the main pulmonary trunk. Consecutive 
2-dimensional orthogonal planes along the main pulmonary trunk were then fit to a modified Guassian function, by a 
process of two-stage numeric optimization. The vessel diameter estimation was performed using a technique of 
multidimensional, constrained non-linear least squares titting and a. variant of the Levenberg-Marquardt least squares 
minimization implemented by Manolis Lourakis l7 was used under the tenus of the GNU 'General Public Liccns~3. To 
estimate artetial distens ibility~ the data were tit to a morplu:mlctric model of ihe pulmonary arterial tree, wh.ich 
incorporates a well-accepted model of pulmonary anerial distensibiHty using lite unconstmined mul tivariable nOD-linear 
optimization function ' tin inw)c' in the Matlab optimization toolbox (MathWorks. Natick, MA). 
3. RESULTS 
Statisticsal significance was determined by performing paired t-test and a one way ANOV A and a1l1fraphs plot mean 
values with standard error bars. CI-I significantly increased the hematocrit, however, there was no significant diffL'I"CnCC 
in hematocrit levels in rats treated with capropril and those provided only water. Hematocrit in CH and CH+PLPAO 
groups was not significantly different ,vith and without captopril treatment. However, there is a statistically significant 
difference be·"h¥e~n the hematocrit of the PLPAO nomloxic group and all the other groups, p<O.02S. Hypoxia is a 
significant stimulus for red blood cell production and captopril treatment did not a lter the stimulus effect. 
ACE activity was inhibited in the rats that were treated with captorpi l, confimled by the decreased mean surface area 
],roduct in treated rats. The ACE activity was not significantly different in the CH, CH+PLPAO. and PLPAO normoxic 
rats that did not rccci\',"~ captopril treatme,nt. 
.' 
Figure 1. Hematocrit 
Bars rcpn'S{'iIt tnt! mean Hilue q{ht'matocrit in Cf{·". PlPA(). 
eH 1 PLPAO w/ captoplil. ('fl, elf w/ captopri! and PLPAO 
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(!'igure 2. 1'ot21 Lung ACE ActiYity 
/Jars represem the meal! value (Jfrm,~/ IUllg ACE actil-ity as meall 
slIr/ace area product mea.mred in iso/arM JUIIg.tj;·om (1{-PLPAO. 
CH+PLP.40 jot.;! captopl'll. CN. ell wi captoprii. mid PLPAO NOf7lloxia 
r.1lS. F.n·or bars arc ±Sf<llItfard error . f<p < 0.00 .1 
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Rals in Ihe CH and CH+PLPAO groups (whelher trealed 
or nOI) had significantly increased RVH compared 10 
PLPAO nonnoxic rats as seen in Figure 3 with a 
p<O.OO l. A hhough there was a tendency toward a 
further increase in RVH. the RVI LV + Septum mass 
ratio was not statistic,ally significantly different betw~n 
the CH and (,H~ PLPAO groups. This is an indicalor 
that the in vivo pulmonary vascular resistance likely 
remained elevated in rats treated with captopril. 
pulmonary pressum versus flu\v data below supports 
th is. 
The lung hemodynamic data is presented in Figure 4. 
The main pulmonary artory pressures measured at the 
various flow rates are graphed with flow normalized to 
body weight, Tile PA pressure is significantly increased 
in lhc CH and CH+PLPAO lrealmenl and non-LreaLmenl 
groups compared to normo:x;ia, as expected. However. 
Figure 4 shows no significance-di fference in pulmonary 
vasclllat resistance of any of the ell animals , whetber 
with or wi thout PLPAO or with or without c.aptopriL 
Treatment w ith capropril did not lower the pulmonary 
vascular resistance and the pressure obtained for a given 
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Figure 3. Righi: Venlyicular Hypertrophy 
RighI Ventricular l1.lpertroph)' is (':rprt~.'i~'{'d (IS the RVILV+Sl'PIUnI ratio. 
Bars repreS(?f!( the mealll'O/lles in CH+/'LPAO. Cll+PLPAO wi 
;:.'1plopril. CH. CH wi captopril, ttlld PI.P AO IItJl1lloxia, Error barJ ar~ ± 
slamumJ error, Qp< O,OOl 
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"~igure 4. Uemodynamics of Full LWlg 
- " ' PLPAO Normoxia 
- · -CII 
- - CH w/ Captopril 
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Flow is normalized ;0 rai body weighlllnd is in ul/its of mllkg/mill and pressl!re i ... in mmHg, Erro,' bars are :I:: 
sfwuiard ('/'I'ur 
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Planar angiograms of the contrast filled arteries from selected lungs from each group arc presented-in Figures 5 and 6. 
These images were obtained from the highest (30 mmHg) and lowest (6 mmHg) intravascular pressures measured. 
The images of both treated and non-treated groups shmv fe'wer peripheral vessels than the 'PLPAO rats kept in norrnoxia. 
However, the rats treate.d with captopril had less vessel dropout than those that did not receive treatment. This pattero of 
vesseJ dropout was mOTe apparent at the higher intravascular pressure 30 mmHg (Figure 6). The images also show slight 
apparent parenchymal edema in the CH and CH+PLPAO groups compared to the PLl'AO Ilormoxic group. The edema 
appeared more exagge.raccd in the hmgs of ra ts treated with captopril compared to untreated. 
Figure 5. Low-Magnification Imagcs of Fun Lung at 6 mmHg 
Scale iJlllpper right I'p.pl'e.wmts I. 7mm. Arrow llldicfl/(,s area ofPlPAO 
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Figure 6. Low-Mngnmcation Images of Full Lung at 30 mmHg 
Scale ill upper r ighllvpr'f:'Sellt5 I. 7f11m.. An'ow illdit'ares area ofPLPAO 
High-magniti.cation planar angiograms of the distal right arterial tree, presented in Figures 7 and 8. reveal more evidence 
of the vessel dropout in hath CH and CH+PLPAO groups compared to the norrnoxic PLPAO rats. Again, the images 
suggest that there is less parenchymaJ vessel dropout ill the treatment groups, in particular rats with CH+PLPAO and 
c(lplOprii treatment. I.n ge-neral. there appeared to he Jess dropout in the CH+PLPAO rats compared to exposed to en 
\\rilhout the banding. 
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Figure 7. High Ma.gni.ficratlon of the_Right Lun,g at 6 mmHg 
Scale bal' repro:wems 500W1l 
Figure. 8. High Magnific:lticD of dle Right Lung at 30 mmHg 
SCdle bm" represents 500/fllt 
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Figure 9 shows data from the main right pulmonary arterial trunk measured in micro focal CT inlages for a selected lung. 
The graph presents vessel diameter versus the distance from the arterial inlet, at four intravascular pressures. The grey 
surface represents the fit t{> the morphological model19 and the tilt of the surface along the pressure axis reflects the 
anerial distensibility. 
Figure 9. Principal pathway data for a scltcted lung 
The morphologic model is given in by Eq. 1 belo'w, where D(x,P) represents the vessel diameter, x is the distance ITom 
the inlet, P is the intravascular pressure, D(O,O) is the unstressed diameter of the inlet, a is a distensibility coefficient, c 
is a measure· of the taper of the main tmnk, and LInt is the total length of the main trunk 1 OJ, 
D(x,P) '" D(O,O)(l + aPJ.l_--=-)'· 
'\. L tot 
Eq. (I) 
Morphologic data is shown in Table I. This data indicates distensibility (a) was unchanged by captopril treatment. The 
pulmonary artery inlet diameter,D(O,O)) and the total length ofthc pHlmonaPJ lnmk.,Ltub were not diff(~rcnt between 
captopril treated and non-treated rats. 
CH+PLPAO wi 
eH CH wI capt9pril CH+PLI'AO captopril 
(n - 3) (n = 2) (n - 4) in =--, 4) 
No. Vessels 
Measured 445 ± 13 408 ± 1 409±9 389 ± 10 
0(0,0) (mm) 1.73± 0.19 1.75 ± 0.33 1.86 ± 0.14 1.806 ± 0.232 
Ltot(mm} 55 ± 1 53 ± 1 53 ± 1 53", 1 
a (1/mmHg) 0.017 ± 0.002 0.012 ± 0.0008 0.012 ± 0.003 0.017 ± 0.003 
Table 1. Morphometric Data. No of vessel segments along the main pulmonary trunk used: jn the analysis, D(O~O) is the 
unstressed vessel diametc~ at the ar terial trunk in~et, Ltot is the total length ofthe main trunk, and a is the artcriaj tree 
dist!;!nsibHity. 
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4. DISCUSSION 
There are few studies evaluating the effect of ACEI on vascular remodeling in a rat model of established pulmonary 
hypertensionLB.::'Z. Previous stucties, in which PH is already established, have shown mixed hemodynamic changes with 
ACE' treannent. Nong ct al. showed thai Ireatment with ACE! (quinapril) in established PH did reduce lhe pulmonary 
artery prcsstU'c and degree nfvascular rcmodding22, while Clozel et a1. showe.d a decrease- in pulmonary artery pressure 
and hematocrit with treatment with cilazapril'. Jeffery ct al. showed mixed eiTects based on the dose ofperindopril with 
higher doses causing a slight reduction in pulmonary artery pressures u . This srudyis unique in thaI' we used CT imaging 
techniques to further interpret the hemodynamic data obtained. Thc C 1" images were, used to quantify morphology and 
biomechanics in the pulmonary arterial tree. The planar images, in conjunction \vith the morphometric data. provide a 
picture of practically tixcd dis1ensibility between treatment and non-treatment groups with less vessel dropout 
peripherally in the treatment groups. The high-rnagnitication planar angiograms indicate les& vessel dropout in the 
tre·atment groups versus the non-treatment groups, which may be mitigation or a change in the evolution , of vElscular 
remodeling. This would suggest that there should be less elevation in the PVR of the rats treated with captopril. 
Ho.wever, our hemodynamic and right ventricular hypertrophy data is contrary and shows no dilTerence in PVR or RVH 
between treated and non-treated rats. The morphologic. anatysis shows no statistically significant differences in diameter, 
length, or distensibility belween the rats lhat received c.ptopril and those that did not. These result, imply lhal although 
there are more arterial vessels present in the caplopril trealed lungs, Ihe newlOrk of vessels present have a larger PVR. 
This increase in PVR could be, in part. explaiD<.·d by the increased secondary parcnc.hyrnal ed~ma present in the captopril 
treated rats. This would be especiaJly the ('·ase in vivo given the high hematoc·rit levels seen in these animals]". The 
increase in parenchymal edema results in stitT and less compliant lungs. whicb may translate to the persistent elevation in 
PVR de~pite more peripheral vessels. Interes(ingly~ L,O! was not was increased with captopril treatment. If anything. the 
CT data suggests the CH group tended to have a longer tmnk len!,'lh. These findings most likely indicate that any 
dongation is occ.urring in the larger vessel. Because uur current analysis relies on detection of a single main tnmk, 
evaluation of peripheral density is not adequately represented by It(lt. 
The CH+PLPAO model was used to simulate the increased flow that is seen in pediatric patients with congenital heart 
disease. There is no statistically significant ditTerellce. in the me.asured arterial distensibility between CH and 
CH+PLPAO with or vlithOllt treatment, but the hcmodynamk,s show a trend toward higher PA pressures in the 
CH+PLPAO groups as well as a trend toward a higher degree of RVH. This suggests thai CH+PLPAO results in a 
higher in vivo PA pressure or there is hematopoietic or other signaling that results from the PLPAO banding, Increased 
flow and shear stress, causing more endothelial injury, may be a dependent factor that atTects the condition of the right 
heart. This relationship would nocd to be further evaluated with additional studies, 
CT angiography in models of lung disease in small animals described by Shingrani ct al'" and Molthen et .1 " is a 
relatively new method tor. assessing (he pulmonary vascular tree. Imaging of (he vascular bed allows for morphometric 
and biomechanical information 10 be obtained, which can tben be used in conjunction wilh biochemical studies to further 
utilor ·lhcrapies. Although captopril did not have a net beneficial effect on hemodynamics of the pulmonary vasculature 
in this s1udy. ACEI treatment did afl'ect the vascular morphology of the· pulmonary arterial bed. This suggests that 
although c::1ptopril by itself may not provide a benefit to pulmonary hemodynamics, its use in altering the vcssel 
morphology may be through combinational therapies. 
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